KR20210130538A - Composition for preventing or treating sarcopenia comprising curcuma extract - Google Patents

Abstract

The present invention relates to a composition for preventing or treating sarcopenia containing a Curcuma longa extract as an active component, and a method for manufacturing the same. The Curcuma longa extract according to the present invention can be used as a pharmaceutical composition useful for preventing and treating sarcopenia, or can be used as a food composition useful for alleviating sarcopenia.

Description

A pharmaceutical composition for preventing or treating sarcopenia comprising a turmeric extract {Composition for preventing or treating sarcopenia comprising curcuma extract}

The present invention relates to a composition for preventing or treating sarcopenia comprising a turmeric extract (Curcuma longa), and a method for preparing the same. It can be used as a composition.

The main causes of sarcopenia are nerve damage, skeletal muscle damage, decreased activity due to damage to the knee joint, use of glucocorticoids, cancer, aging, etc. (Document 1. Vikas D., 2015). A decrease in muscle mass due to sarcopenia can affect overall physical health by causing a decrease in metabolism, adult disease caused by an increase in body fat, and bone disease.

A method of inducing sarcopenia by promoting catabolism of skeletal muscle by treatment with dexamethasone is known through many studies (Document 2. Andre LK., 2016). In the case of dexamethasone-induced sarcopenia in mice, grip strength and muscle mass are reduced. Such an example can be confirmed as an example in which a decrease in grip strength and muscle mass is recovered when Schisandra extract is ingested in mice induced by sarcopenia by dexamethasone (Document 3. Kim JW., 2015) .

However, there is no study on the inhibition of sarcopenia of the turmeric extract because there is no teaching that it contains turmeric extract as an active ingredient and inhibits sarcopenia.

[Document 1] Vikas D., et al., Pharmacological research., 99, 86-100, 2015 [Document 2] Andre LK., et al., Muscle & Nerve., 53, 779-788, 2016 [Document 3] Kim JW., et al., International journal of molecular medicine., 36, 29-42, 2015 [Document 4] Louay L., International journal of pharmaceutical and biomedical research., 5, 17-23, 2014 [Document 5] Nicastro H., Nutrition., 28, 465-471, 2012 [Document 6] Sun L., et al., Biochemical and biophysical research communications., 487, 83-89, 2017

Accordingly, the present inventors tried to find a natural material for inhibiting sarcopenia in order to develop a preventive or therapeutic agent for sarcopenia. As a result, the present invention was completed by confirming that a turmeric extract rich in curcumin and the like inhibits sarcopenia induced by dexamethasone and preserves muscle mass.

Accordingly, an object of the present invention is to provide a composition for preventing or treating sarcopenia comprising a turmeric extract as an active ingredient.

Another object of the present invention is to provide a food composition for improving sarcopenia comprising a turmeric extract as an active ingredient.

Another object of the present invention relates to the use of a turmeric extract for the prevention, treatment or improvement of sarcopenia.

The present invention relates to a composition for preventing or treating sarcopenia comprising an extract of turmeric as an active ingredient. .

Accordingly, the present invention will be described in more detail.

The present invention provides a pharmaceutical composition for preventing or treating muscle loss comprising the turmeric extract as described above as an active ingredient. The turmeric extract includes a solvent crude extract of turmeric and is the same as described above.

Turmeric is a perennial plant belonging to the ginger family, belongs to the root plant, and is well known as a spice for curry and the like. As a perennial plant (Curcuma longa Rhizoma), turmeric is usually used as a powdered rhizome, and some rhizomes are used as a whole. It is mainly cultivated in the subtropical regions of Southeast Asia from southern China. At first it was used as a dye, then it was used as a medicine, and it was also used as a spice. Such turmeric is currently known to have effects such as antioxidant, anticancer, anti-inflammatory, and liver protection (Document 4. Louay L., International journal of pharmaceutical and biomedical research., 5, 17-23, 2014).

However, a number of prior literatures on the muscle disease treatment efficacy of turmeric-derived components were searched, but the prior literature (Korean Patent Publication No. 10-2017-0002443) suggesting the efficacy of curcumin for improving muscle performance was found in the treatment of sarcopenia of turmeric extract. No use was given. In addition, there was (Korean Patent Publication No. 10-2019-0073967) containing isolate soybean protein and curcumin as active ingredients, but there was a difference from the present invention containing a turmeric extract as an active ingredient.

That is, in these prior documents, there is no disclosure about the inhibition of sarcopenia of the turmeric extract, and there is no description of the solvent extract according to the present invention.

The present invention relates to an extract having muscle loss inhibitory activity, including an extract of turmeric, wherein the 'extract' includes a solvent crude extract, a specific solvent soluble extract (solvent fraction), and a solvent fraction of the solvent crude extract, The turmeric extract may be in a solution, concentrate or powder form.

The turmeric extract according to the present invention is a crude extract obtained by extracting one or more selected from the group consisting of stems and roots of turmeric with one or more solvents selected from the group consisting of water, and a linear or branched alcohol having 1 to 4 carbon atoms. can be

The extract may be obtained by extraction with water, but is not limited thereto.

The manufacturing process of the turmeric extract according to the present invention will be described in more detail as follows: Curcuma is cut, washed with water to remove stenosis and dried, and then, about 80 to 120 times by volume, preferably based on the weight of the turmeric. is extracted under reflux with 95 to 105 volume times the extraction solvent. After extraction, the filtrate is collected by filtration. The extraction temperature is not particularly limited, but may be 40 to 110°C, 50 to 110°C, 60 to 110°C, 70 to 110°C, and preferably 80 to 110°C.

If the amount of the solvent used in the preparation of the turmeric extract is too small, stirring is difficult, the solubility of the extract is lowered, and the extraction efficiency is lowered. Since handling problems may occur, the amount of the solvent used is preferably within the above range.

The filtered extract thus obtained may be at 40 to 60°C and 40 to 55°C in order to control the content of remaining moisture to be suitable for use as a pharmaceutical raw material, preferably 700 under the conditions of 45 to 55°C. to 800 mmHg under reduced pressure, and dried at -50 to -90°C, preferably -75 to -85°C using a freeze dryer to prepare a turmeric extract.

The extraction method according to the present invention may be any method commonly used, for example, cold extraction, hot water extraction, ultrasonic extraction, or reflux cooling extraction method, but is not limited thereto.

The turmeric extract according to the present invention may be reflux extraction of dried turmeric with a solvent.

The reflux extraction is a method of extracting the extraction target material while the extraction solvent flows. During extraction at high temperatures, organic solvents such as water and ethanol will volatilize during extraction.

Sarcopenia according to the present invention may be caused by one or more causes selected from the group consisting of nerve damage, skeletal muscle damage, reduced activity due to damage to the knee joint, use of glucocorticoids, cancer, and aging.

The sarcopenia is caused by degeneration of spinal nerves, motor nerves, or skeletal muscle fibers, and is one of the representative intractable diseases for which the cause of the invention has not yet been identified. The motor nerve that induces the contraction of the skeletal muscle degenerates so that the contraction of the skeletal muscle does not proceed, or the expression of the protein involved in the contraction of the muscle in the skeletal muscle is reduced or the protein is modified so that the contraction of the normal skeletal muscle does not proceed, and in the long term It is known that the motor nerve or skeletal muscle is transformed into a fibrous tissue.

Since the root cause of such sarcopenia has not yet been identified, and a method for preventing or recovering the degeneration of motor nerves or skeletal muscle has not been developed, at present, a method for slowing the progression of sarcopenia has been developed. Research is being actively carried out for

The composition according to the present invention may be administered to mammals including humans by various routes. The administration method may be any method commonly used, for example, may be administered by routes such as oral, dermal, intravenous, intramuscular, subcutaneous, etc., and preferably orally.

The composition can be prepared in oral dosage forms such as powders, granules, tablets, capsules, ointments, suspensions, emulsions, syrups, and aerosols, or parenteral dosage forms in the form of transdermal preparations, suppositories, and sterile injection solutions according to conventional methods, respectively. It may be formulated and used, and may further include adjuvants such as pharmaceutically suitable and physiologically acceptable carriers, excipients and diluents.

Carriers, excipients and diluents that may be included in the composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

When formulating the composition, commonly used fillers, extenders, binders, wetting agents, disintegrants, diluents or excipients such as surfactants may be used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the extract, for example, starch, calcium carbonate, sucrose ( sucrose) or lactose, gelatin, etc. may be mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used.

Oral formulations of the composition include suspensions, solutions, emulsions, syrups, ointments, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. may be included.

Formulations for parenteral administration of the composition may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, transdermal preparations, and the like. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

As the preparation of the suppository of the composition, witepsol, macrogol, tween 61, cacao butter, laurin fat, glycerogelatin, etc. may be used.

In an embodiment in which the composition according to the present invention is applied to humans, the turmeric extract composition according to the present invention may be administered alone, but in general, the pharmaceutical composition selected in consideration of the administration mode and standard pharmaceutical practice It may be administered in admixture with a carrier.

For example, the turmeric extract composition of the present invention may be in the form of a tablet containing starch or lactose, or in the form of a capsule containing alone or an excipient, or an elixir or suspension containing a chemical agent for flavoring or coloring It may be administered orally, orally or sublingually in the form. Such liquid formulations may contain suspending agents (eg, methylcellulose, semisynthetic glycerides such as witepsol or mixtures of apricot kernel oil and PEG-6 esters or PEG-8 and caprylic/capric glyceride mixtures, such as mixtures of glycerides).

The dosage of the turmeric extract composition may vary depending on the patient's age, weight, sex, dosage form, health status, and disease level, and administered in divided doses from once a day to several times a day at regular time intervals according to the judgment of a doctor or pharmacist You may.

The turmeric extract has a daily dose of 0.3 to 3.0 g/kg, 0.3 to 2.7 g/kg, 0.3 to 2.4 g/kg, 0.3 to 2.1 g/kg, 0.8 to 3.0 g/kg, 0.8 based on the active ingredient content. to 2.7 g/kg, 0.8 to 2.4 g/kg, 0.8 to 2.1 g/kg, 1.3 to 3.0 g/kg, 1.3 to 2.7 g/kg, 1.3 to 2.4 g/kg, 1.3 to 2.1 g/kg, 1.8 to 3.0 g/kg, 1.8 to 2.7 g/kg, 1.8 to 2.4 g/kg, 1.8 to 2.1 g/kg, and preferably 2.0 g/kg. As an example, the dosage may be higher or lower depending on individual differences.

If the daily dose of the turmeric extract according to the present invention is less than the dose, a significant effect cannot be obtained. Therefore, it is preferable to set it within the above range.

In another aspect, the present invention provides a food composition for improving chronic pain comprising the turmeric extract as described above. The food composition may be various foods, beverages, food additives, and the like.

In one embodiment of the present invention, the turmeric extract contains at least one solvent selected from the group consisting of stems and roots of turmeric, water, and one or more solvents selected from the group consisting of linear or branched alcohols having 1 to 4 carbon atoms. It may be a crude extract obtained by extraction with

The extract may be obtained by extraction with water, but is not limited thereto.

The extraction method of the turmeric extract according to the present invention may be any commonly used method, for example, cold extraction, hot water extraction, ultrasonic extraction, or reflux cooling extraction method, but is not limited thereto.

The turmeric extract according to the present invention may be reflux extraction of dried turmeric with a solvent.

The reflux extraction is a method of extracting the extraction target material while the extraction solvent flows. During extraction at high temperatures, organic solvents such as water and ethanol will volatilize during extraction.

Sarcopenia according to the present invention may be caused by one or more causes selected from the group consisting of nerve damage, skeletal muscle damage, reduced activity due to damage to the knee joint, use of glucocorticoids, cancer, and aging.

The content of the turmeric extract as an active ingredient included in the food composition according to the present invention is not particularly limited as appropriate depending on the form, use, etc. of the food, for example, it can be added as 0.01 to 30% by weight of the total food weight, health drink composition Silver may be added in a proportion of 0.03 to 0.3 g, preferably 0.2 g, based on 100 ml.

The health beverage composition according to the present invention has no particular limitation on the liquid component other than including the extract as an essential component in the indicated ratio, and may include various flavoring agents or natural carbohydrates as additional components like a conventional beverage. . Examples of the above-described natural carbohydrates include monosaccharides, such as disaccharides such as glucose, fructose, and the like, such as maltose, sucrose, and the like, and conventional polysaccharides such as dextrin, cyclodextrin, and the like. sugar and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatine, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.In addition to the above, the composition of the present invention contains various nutrients, vitamins, minerals (electrolytes), and synthetic flavors. Flavoring agents and natural flavoring agents, etc., coloring and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols , a carbonation agent used in carbonated beverages, etc. In addition, the compositions of the present invention may include natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages.These components may be independently or in combination The proportion of these additives is not critical, but is generally selected from 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

In the case of ingesting the food composition according to the present invention, in view of the general characteristics of natural extracts, it is considered that there is no concern about side effects compared to other synthetic drugs, and in fact, as a result of toxicity test for standardized herbal composition, there is no effect on the living body. turned out to be

The present invention relates to a composition for preventing or treating sarcopenia comprising a turmeric extract or a compound isolated therefrom as an active ingredient, and a method for preparing the same, wherein the turmeric extract according to the present invention exhibits excellent effects in inhibiting sarcopenia, etc. , It can be used as a pharmaceutical composition useful for preventing and treating sarcopenia, or as a food composition useful for improving sarcopenia.

1 is a schematic diagram showing a manufacturing process of a turmeric extract according to a preparation example of the present invention.
2 is a schematic diagram showing the design of an animal model with reduced muscle according to Example 1 of the present invention.
3 is a graph showing the results of measuring grip strength for 14 days after administration of dexamethasone to an animal model with reduced muscle according to Example 2 of the present invention.
4 is a graph showing the muscle weight (%) compared to the body weight of the muscle reduction animal model according to Example 2 of the present invention.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.

manufacturing example. Preparation of turmeric extract

Preparation of water extract

Turmeric (Curcuma longa L.) was collected from Jindo, Jeollanam-do, and the turmeric extract was prepared at the Natural Resources Research Center located in Jangheung, Jeollanam-do.

As shown in Figure 1, 60 kg of dried and pulverized turmeric was added to 6000 L of a 100% water solvent, extracted under reflux at 100° C. for 4 hours, and then cooled, and the precipitate was removed using a centrifugal separator. Then, the impurities were filtered and the filtrate was collected. Then, the filtrate was concentrated under reduced pressure at 50 °C and 750 mmHg, frozen at -70 °C, and dried in a freeze dryer for 5 to 7 days to obtain 5800 g (yield: 9.68%) of turmeric extract.

Example 1. Establishment of an animal model of sarcopenia

8-week-old male ICR mice were acclimatized to the breeding room environment for 1 week, and then used for the experiment. The room temperature and humidity of the mouse breeding room were adjusted to 23±3° C. and 55±15%, and the illumination time was set to 12 hours from 7 am to 7 pm. Drinking water was used to water the mice, and the experiment was designed so that food and water were freely ingested during the experiment period. A general diet (5L79, orient, Korea) was used for the mouse diet, and the diet was adjusted with the composition shown in Table 1.

product # AIN-93G kcal% protein 20 Fat 9.6 crude fiber 4.6

In order to confirm the sarcopenia inhibitory ability of the turmeric extract obtained through a preparation example of the present invention, the method described in Citation 2 was applied. Citation 2 discloses that a ladder exercise is performed by hanging a weight of 80% of the weight on the tail of a rat for 8 weeks, and dexamethasone is administered 10 days before the end of the experiment to induce sarcopenia. In the present invention, the method of Citation 2 was applied, but mice were used instead of rats as experimental animals. In addition, exercise was carried out by attaching a weight of 100% of body weight instead of 80% of body weight to the tail for about 5 weeks.

In addition, by applying the method described in Citation 5, dexamethasone was administered intraperitoneally at a concentration of 1 mg/kg body weight/day. Concentration 1 mg/kg body weight/day For intraperitoneal administration of dexamethasone, when various concentrations were treated in other studies, the lowest concentration was used.

As shown in Figure 2, 24 mice that had undergone a one-week pre-bringing period were acclimatized to ladder walking for two weeks. The mice were allowed to climb the ladder at an angle of 70 to 80 degrees with the ground 8 times, and a total of 6 times (2 weeks x 3 times = 6 times in total) during the 2 weeks of the adaptation period was performed. At this time, in order to adapt the mouse to the weight of the weight, a ladder exercise was performed by hanging 50% of the weight of the mouse on the tail. This experiment was carried out when the weight of the weight was increased by 10% for each exercise and reached 100% of the body weight.

Mice, which had undergone an adaptation period for a total of 2 weeks, were divided into three groups as shown in Table 2.

In each of the three groups, 100% of the body weight was hung on the tail for a total of 3 weeks, and the ladder exercise was performed in which the 70-degree ladder was reciprocated 8 times. In addition, distilled water, turmeric extract and dexamethasone were administered under the conditions shown in Table 2.

Distilled water CLW DEX group CON O X X group DEX O X O group CLW X O O

The control group, CON (control) group, was administered with distilled water by oral administration, and CLW (Curcuma Longa Water extract) group was administered with 1 g/kg body weight/day of turmeric extract by oral administration and dexamethasone by intraperitoneal administration. In addition, the DEX (dexamethasone) group was administered with distilled water by oral administration and dexamethasone by intraperitoneal administration.

During the first week of the experiment, distilled water was orally administered to the CON group and DEX group, and turmeric extract was orally administered to the CLW group. Then, for 2 weeks, dexamethasone was administered only to the DEX group and the CLW group to create conditions such as sarcopenia.

Example 2. Measurement of grip strength in mice

In order to confirm the effect of turmeric extract on the inhibition of sarcopenia, a grip test was performed. The grip test of this experiment was conducted by applying the method of Citation 6, and the grip strength was measured by placing the mouse on the footrest of the grip strength meter and pulling the tail of the mouse to determine the force when falling. was measured using The results of measuring grip strength after dexamethasone administration are shown in Table 3 below.

0 day 7 days 21 days CON(g) 279.4 ± 5.14 283.5 ± 8.43 295.2 ± 6.51 DEX(g) 273.8 ± 12.21 238.7 ± 6.42 223.5 ± 8.36 CLW(g) 272.7 ± 9.59 256.5 ± 6.06 268.4 ± 5.26

When the grip strength of each group was measured before this experiment, the CON group was 279.4 ± 5.14 g, the DEX group was 273.8 ± 12.21 g, and the CLW group was 272.7 ± 9.59 g, and there was no significant difference in the strength of the force between the groups.

For a week (7 days in total) from the start of the experiment, distilled water was administered to the CON group and DEX group, and turmeric extract was administered to the CLW group, and all three groups performed ladder exercise under the same conditions. As a result of measuring the grip strength one week after the start of the experiment, the CON group showed a change in grip strength of 4.1 ± 3.29 g. The DEX group showed a change in grip strength of -35.1±5.79 g. The CLW group showed a change in grip strength of -16 ± 3.53 g.

For two weeks (14 days in total) from one week after the experiment, distilled water was administered to the CON group in the same way as before. On the other hand, the DEX group and the CLW group were administered dexamethasone, a substance that induces sarcopenia. In addition, along with the administration of dexamethasone, the DEX group was administered with distilled water, and the CLW group was administered with a turmeric extract. The same ladder exercise was performed while proceeding with each administration method. Then, the grip strength was measured two weeks after the experiment. The CON group showed a change in grip strength of 11.7 ± 1.92. The DEX group showed a change in grip strength of -15.2±1.94. On the other hand, the CLW group showed a change in grip strength of 11.9±0.8.

As a result of the experiment for a total of 3 weeks, it was confirmed that muscle loss was inhibited by about 1.2 times in the CLW group compared to the DEX group, and the results are shown as a graph in FIG. 3 . Through this, it was confirmed that the turmeric extract was effective in inhibiting the decrease in muscle strength due to sarcopenia.

Example 3. Measurement of muscle weight in mice

Example 2 After the experiment, the mice of each group participating in the experiment were dissected, and the middle broad muscle and the calf muscle among the leg muscles were collected, and then their weight was measured. The muscle weight (%) relative to the mouse weight is shown in Table 4 and FIG. 4 below.

medium broad muscle calf muscles CON(%) 1.24 ± 0.06 0.98 ± 0.03 DEX(%) 1.04 ± 0.04 0.82 ± 0.03 CLW(%) 1.18 ± 0.04 0.91 ± 0.02

As a result of the experiment, the middle broad muscle and calf muscle in the CON group were 1.24 ± 0.06, 0.98 ± 0.02%, the DEX group was 1.04 ± 0.04, 0.82 ± 0.03%, and in the CLW group, 1.18 ± 0.04, 0.91 ± 0.02% this was The CON group and CLW group did not show a significant difference in muscle mass change, but compared to the rest of the groups, the CLW group showed a 1.1-fold increase in the middle broad muscle and a 1.1-fold increase in the calf muscle compared to the DEX group. In addition, it was confirmed that there was little difference in muscle mass compared to the CON group in which sarcopenia was not induced because dexamethasone was not administered. Through this, it was confirmed that the turmeric extract inhibited sarcopenia caused by dexamethasone.

Example 4. Preparation method of formulation

4-1. Preparation of powders

CL 200 mg

Lactose 100 mg

talc 10 mg

The above ingredients are mixed and filled in an airtight bag to prepare a powder.

4-2. manufacture of tablets

CL 200 mg

100 mg cornstarch

Lactose 100 mg

2 mg magnesium stearate

After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet manufacturing method.

4-3. Preparation of capsules

CL 200 mg

3 mg of crystalline cellulose

Lactose 14.8 mg

0.2 mg magnesium stearate

According to a conventional capsule preparation method, the above ingredients are mixed and filled in a gelatin capsule to prepare a capsule.

4-4. Preparation of liquids

CL 200 mg

10 g isomerized sugar

5 g of mannitol

Purified water appropriate amount

The preparation method of the liquid preparation was according to a conventional method.

Each component was dissolved in purified water. Each component dissolved in purified water was mixed and an appropriate amount of lemon flavor was added. Additional purified water was added to the prepared mixture to adjust the total volume to 100 ml, and then filled in a brown bottle and sterilized.

4-6. Preparation of food compositions

CL 1000 mg

appropriate amount of vitamin mixture

70 μg vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

0.2 μg of vitamin B12

Vitamin C 10 mg

Biotin 10 μg

Nicotinamide 1.7 mg

50 μg folic acid

Calcium pantothenate 0.5 mg

Mineral mixture appropriate amount

Ferrous sulfate 1.75 mg

Zinc oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

The composition ratio of the vitamin and mineral mixture is relatively suitable for a food composition in a preferred embodiment, but the mixing ratio may be arbitrarily modified. Next, granules are prepared and can be used for preparing food compositions according to a conventional method.

4-7. manufacture of health drinks

CL 1000 mg

citric acid 1000 mg

100 g of oligosaccharides

2 g of plum concentrate

1 g taurine

Total 900 ml with purified water

After mixing the above ingredients according to the usual health drink manufacturing method, after stirring and heating at 85°C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2L container, sealed and sterilized, then refrigerated. It is used in the manufacture of the health drink of the invention.

Although the composition ratio is prepared by mixing ingredients suitable for relatively favorite beverages in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and national preferences such as demand class, demanding country, and use.

Claims (9)

A pharmaceutical composition for preventing or treating sarcopenia comprising a turmeric ( Curcuma longa ) extract as an active ingredient. The pharmaceutical for preventing or treating sarcopenia according to claim 1, wherein the turmeric extract is a crude extract obtained by extraction with one or more solvents selected from the group consisting of water and a linear or branched alcohol having 1 to 4 carbon atoms. composition. The pharmaceutical composition for preventing or treating sarcopenia according to claim 2, wherein the extract is obtained by extraction with water. The muscle according to claim 1, wherein the sarcopenia is caused by one or more causes selected from the group consisting of nerve damage, skeletal muscle damage, reduced activity due to knee joint damage, use of glucocorticoids, cancer, and aging. A pharmaceutical composition for preventing or treating hypothyroidism. The pharmaceutical composition for preventing or treating sarcopenia according to claim 1, wherein the daily dose of the composition is 0.3 to 3.0 g/kg based on the active ingredient content. A food composition for improving sarcopenia comprising a turmeric ( Curcuma longa ) extract as an active ingredient. The food composition for improving sarcopenia according to claim 6, wherein the turmeric extract is a crude extract obtained by extraction with one or more solvents selected from the group consisting of water and a linear or branched alcohol having 1 to 4 carbon atoms. The food composition for improving sarcopenia according to claim 7, wherein the extract is obtained by extraction with water. The muscle according to claim 6, wherein the sarcopenia is caused by one or more causes selected from the group consisting of nerve damage, skeletal muscle damage, reduced activity due to knee joint damage, use of glucocorticoids, cancer, and aging. A food composition for improving hypothyroidism.

Images